536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours. - Adjei, A.A.; Beg, M.; Melear, J.; Thompson, J.; Tsai, F.Y-C.; Baranda, J.C.; Bastos, B.; Spira, A.; Lou, Y.; Seetharam, M.; Uemura, M.; Camidge, D.R.; et al. (Annals of Oncology, 2020)